The efficacy and safety of immune combination therapy in patients with driver gene-negative non-small cell lung cancer with liver metastasis: a systematic review and network meta-analysis
OncologiaSobre o estudo
- Desenho
- Revisão sistemática
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- BMC cancer
- Publicado em
- 18 ago 2025
- Citações
- 4
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
The efficacy and safety of immune combination therapy in patients with driver gene-negative non-small cell lung cancer with liver metastasis: a systematic review and network meta-analysis
Weixing Zhao, Bo Li, Yujia Gu, Xiaoni Jin, Zirui Li, Wanjing Guo, Xinxin Lu, Jun Jiang
Descritores MeSH
- Immune Checkpoint Inhibitors
- Antineoplastic Combined Chemotherapy Protocols
- Carcinoma, Non-Small-Cell Lung
- Immunotherapy
- Liver Neoplasms
- Lung Neoplasms
- Clinical Trials, Phase III as Topic
- Humans
- Randomized Controlled Trials as Topic
- Treatment Outcome
Veja também
Estudos relacionados
- Impact of adding immune checkpoint inhibitors to standard therapies in non-small cell lung cancer: A systematic review of efficacy outcomes
- Correlation of ORR and PFS with OS outcomes in phase III trials of immunotherapy in advanced NSCLC: Systematic review and meta-analysis
- First-line PD-1/PD-L1 inhibitors plus chemotherapy vs. chemotherapy alone in stage IIIB-IV non-squamous NSCLC: an updated meta-analysis of phase 3 RCTs
- PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for Chinese patients with advanced non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized controlled trials